{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:55:12Z","timestamp":1789689312406,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the process of guideline development, expert opinion is introduced when there is low-quality or no scientific evidence available. During the first revision of the European phenylketonuria guidelines, the limited data regarding adult treatment targets was interpreted and weighted in different ways by different professionals. In this study, we have recorded and analyzed personal experience and views that may affect decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A web-based questionnaire was sent to all panelists involved in the revision of the guidelines (n\u2009=\u200923), evaluating demographics, opinion about treatment targets, interpretation of scientific data and general views to establish adult specific treatment guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>19 panelists responded. Most acknowledged the importance of maintaining metabolic control even in adulthood with target levels in line with previous recommendations, but that dietary treatment is a limiting factor for social life. 68% preferred the risk of over-treatment rather than undertreatment. The great majority considered cognitive, behavioral and wellbeing measures to be critical to measure treatment success. 58% considered significant group differences of 1 SD or less in neuropsychological tasks to be clinically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results highlight differences in expert opinions and the importance of making them more transparent to reach less-biased recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03983-y","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:17:05Z","timestamp":1762780625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The influence of professionals\u2019 personal views and values in the development of guidelines for rare diseases: an example from phenylketonuria"],"prefix":"10.1186","volume":"20","author":[{"given":"Annemiek M. J.","family":"van Wegberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3773-1929","authenticated-orcid":false,"given":"Francjan J.","family":"van Spronsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"10092","key":"3983_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0140-6736(16)31592-6","volume":"390","author":"B Djulbegovic","year":"2017","unstructured":"Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017;390(10092):415\u201323.","journal-title":"Lancet"},{"key":"3983_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2018.09.007","volume":"104","author":"SA Li","year":"2018","unstructured":"Li SA, Alexander PE, Reljic T, Cuker A, Nieuwlaat R, Wiercioch W, et al. Evidence to decision framework provides a structured \u201croadmap\u201d for making grade guidelines recommendations. J Clin Epidemiol. 2018;104:103\u201312.","journal-title":"J Clin Epidemiol"},{"key":"3983_CR3","doi-asserted-by":"publisher","first-page":"l4606","DOI":"10.1136\/bmj.l4606","volume":"366","author":"HJ Schunemann","year":"2019","unstructured":"Schunemann HJ, Zhang Y, Oxman AD. Expert evidence in guidelines g. distinguishing opinion from evidence in guidelines. BMJ. 2019;366:l4606.","journal-title":"BMJ"},{"key":"3983_CR4","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A. (2013) GRADE handbook: handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.pq7g5y80zfhj."},{"issue":"2","key":"3983_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2025.109125","volume":"145","author":"AMJ van Wegberg","year":"2025","unstructured":"van Wegberg AMJ, MacDonald A, Ahring K, Belanger-Quintana A, Beblo S, Blau N, et al. European guidelines on diagnosis and treatment of phenylketonuria: first revision. Mol Genet Metab. 2025;145(2): 109125.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3983_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10545-007-0644-5","volume":"30","author":"JG Loeber","year":"2007","unstructured":"Loeber JG. Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis. 2007;30(4):430\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"3983_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","volume":"5","author":"FJ van Spronsen","year":"2017","unstructured":"van Spronsen FJ, van Wegberg AM, Ahring K, Belanger-Quintana A, Blau N, Bosch AM, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3983_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg AMJ, MacDonald A, Ahring K, Belanger-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.","journal-title":"Orphanet J Rare Dis"},{"key":"3983_CR9","first-page":"1","volume":"9","author":"A MacDonald","year":"2016","unstructured":"MacDonald A, Smith TA, de Silva S, Alam V, van Loon JM. The personal burden for caregivers of children with phenylketonuria: a cross-sectional study investigating time burden and costs in the UK. Mol Genet Metab Rep. 2016;9:1\u20135.","journal-title":"Mol Genet Metab Rep"},{"key":"3983_CR10","first-page":"57","volume":"17","author":"S Ford","year":"2018","unstructured":"Ford S, O\u2019Driscoll M, MacDonald A. Living with phenylketonuria: lessons from the PKU community. Mol Genet Metab Rep. 2018;17:57\u201363.","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"3983_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188\u2013200.","journal-title":"Genet Med"},{"issue":"9","key":"3983_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-8587(17)30201-2","volume":"5","author":"P Burgard","year":"2017","unstructured":"Burgard P, Ullrich K, Ballhausen D, Hennermann JB, Hollak CEM, Langeveld M, et al. Issues with European guidelines for phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):681\u20133.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3983_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13023-020-01668-2","volume":"16","author":"NM Burgess","year":"2021","unstructured":"Burgess NM, Kelso W, Malpas CB, Winton-Brown T, Fazio T, Panetta J, et al. The effect of improved dietary control on cognitive and psychiatric functioning in adults with phenylketonuria: the ReDAPT study. Orphanet J Rare Dis. 2021;16(1):35.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3983_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13023-019-1225-z","volume":"14","author":"C Romani","year":"2019","unstructured":"Romani C, Manti F, Nardecchia F, Valentini F, Fallarino N, Carducci C, et al. Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels. Orphanet J Rare Dis. 2019;14(1):273.","journal-title":"Orphanet J Rare Dis"},{"key":"3983_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104925","volume":"143","author":"C Romani","year":"2022","unstructured":"Romani C, Olson A, Aitkenhead L, Baker L, Patel D, Spronsen FV, et al. Meta-analyses of cognitive functions in early-treated adults with phenylketonuria. Neurosci Biobehav Rev. 2022;143: 104925.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"3983_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10545-010-9253-9","volume":"34","author":"AE ten Hoedt","year":"2011","unstructured":"ten Hoedt AE, de Sonneville LM, Francois B, ter Horst NM, Janssen MC, Rubio-Gozalbo ME, et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis. 2011;34(1):165\u201371.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3983_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/jimd.12413","volume":"44","author":"L Aitkenhead","year":"2021","unstructured":"Aitkenhead L, Krishna G, Ellerton C, Moinuddin M, Matcham J, Shiel L, et al. Long-term cognitive and psychosocial outcomes in adults with phenylketonuria. J Inherit Metab Dis. 2021;44(6):1353\u201368.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl","key":"3983_CR18","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.ymgme.2013.08.013","volume":"110","author":"J Weglage","year":"2013","unstructured":"Weglage J, Fromm J, van Teeffelen-Heithoff A, Moller HE, Koletzko B, Marquardt T, et al. Neurocognitive functioning in adults with phenylketonuria: results of a long term study. Mol Genet Metab. 2013;110(Suppl):S44\u20138.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"3983_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2007.05.006","volume":"92","author":"SE Waisbren","year":"2007","unstructured":"Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007;92(1\u20132):63\u201370.","journal-title":"Mol Genet Metab"},{"key":"3983_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13023-015-0294-x","volume":"10","author":"AM Bosch","year":"2015","unstructured":"Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, et al. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015;10:80.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3983_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10545-010-9276-2","volume":"34","author":"C Dawson","year":"2011","unstructured":"Dawson C, Murphy E, Maritz C, Chan H, Ellerton C, Carpenter RH, et al. Dietary treatment of phenylketonuria: the effect of phenylalanine on reaction time. J Inherit Metab Dis. 2011;34(2):449\u201354.","journal-title":"J Inherit Metab Dis"},{"key":"3983_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.664525","volume":"15","author":"CJ McGinnity","year":"2021","unstructured":"McGinnity CJ, Riano Barros DA, Guedj E, Girard N, Symeon C, Walker H, et al. A retrospective case series analysis of the relationship between phenylalanine: tyrosine ratio and cerebral glucose metabolism in classical phenylketonuria and hyperphenylalaninemia. Front Neurosci. 2021;15: 664525.","journal-title":"Front Neurosci"},{"key":"3983_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2021.02.025","volume":"136","author":"B Djulbegovic","year":"2021","unstructured":"Djulbegovic B, Hozo I, Li SA, Razavi M, Cuker A, Guyatt G. Certainty of evidence and intervention\u2019s benefits and harms are key determinants of guidelines\u2019 recommendations. J Clin Epidemiol. 2021;136:1\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"3983_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1258\/jrsm.2010.100104","volume":"103","author":"FM Hajjaj","year":"2010","unstructured":"Hajjaj FM, Salek MS, Basra MK, Finlay AY. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice. J R Soc Med. 2010;103(5):178\u201387.","journal-title":"J R Soc Med"},{"issue":"1","key":"3983_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12909-017-1089-7","volume":"17","author":"D Kozlowski","year":"2017","unstructured":"Kozlowski D, Hutchinson M, Hurley J, Rowley J, Sutherland J. The role of emotion in clinical decision making: an integrative literature review. BMC Med Educ. 2017;17(1):255.","journal-title":"BMC Med Educ"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03983-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03983-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03983-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:09:13Z","timestamp":1762884553000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03983-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3983"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03983-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical consent was not sought as no personal data has been collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The UMCG as employer of A.M.J.v.W. has received research grants, advisory board fees, and\/or speaker's honoraria from Biomarin, Nutricia and PTC Therapeutics, and travel grants from Nutricia and Vitaflo. The UMCG as employer of F.J.v.S. has received research grants, advisory board fees, and\/or speaker's honoraria from Agios, Alexion, AlltRNA, Applied Pharma Research, Arla Food Int., Biomarin, Beatrix Research Fund, ESPKU, Nestle-Codexis Alliance, Moderna, Nutricia, NPKUA, NPKUV, Pluvia Biotech, PTC, Rivium Medical BV, Sobi, Tyrosinemia Foundation, Vitaflo, and ZONMW. C.R. reports no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"571"}}